A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

December 19, 2025

Study Completion Date

December 19, 2025

Conditions

HealthyHIV Pre-exposure Prophylaxis

Interventions

DRUG

MK-8527

Oral administration

Trial Locations (1)

RECRUITING

University of Pittsburgh Medical Center Magee-Womens Hospital, Pittsburgh

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY